

NOVARTIS AG

ISIN: CH0012005267 WKN: 1200526 Asset Class: **Stock**

Company

2024/07/11 17:31:41



Price

99.28 CHF

Difference 1.00%(0.98)



Contact Details

NOVARTIS AG Tel: +41-61-324-11-11
-- Fax: +
Lichtstrasse 35 Web: <http://www.novartis.com>
4056 Basel E-mail: -

Company Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	25,654,333,000		34,149,132,000		41,655,955,000	
Common stock capital		694,361,000		823,428,000		820,946,000
Fixed assets	61,729,135,000		78,507,846,000		82,154,750,000	
Equity capital of a company		39,347,137,000		54,978,159,000		61,796,015,000
Cash and cash equivalents	11,272,218,000		6,954,728,000		11,304,638,000	
Accrued liabilities		2,802,694,000		3,079,065,000		4,279,671,000
Other assets	-		-		-	
Current liabilities		22,211,143,000		26,512,531,000		27,524,019,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		25,825,188,000		31,166,287,000		34,490,672,000
Different income		-		-		-
Other liabilities		1,004,088,000		1,459,965,000		1,343,946,000
Total assets	87,383,469,000	87,383,469,000	112,656,978,000	112,656,978,000	123,810,706,000	123,810,706,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	76,057	101,703	104,323
Equity ratio	45.11%	48.87%	50.03%
Debt-equity ratio	121.69%	104.63%	99.86%

Others

	2023	2022	2021
Tax Expense Rate	6.03%	16.90%	19.62%

Income statement

	2023	2022	2021
Turnover	40,834,735,000	48,273,766,000	47,199,917,000
Net income	7,699,648,000	6,642,477,000	21,961,593,000
EBIT	8,673,367,929	8,876,041,682	10,940,534,610
Operating income before taxes	8,210,082,000	8,003,445,000	9,872,248,000
Cash Flow	12,992,707,000	13,596,306,000	13,778,909,000
Net interest income	-223,764,000	-627,477,000	-766,155,000
Research and development expenses	7,389,613,000	8,484,798,000	8,722,101,000
Income taxes	495,157,000	1,352,372,000	1,937,330,000
Result from investments in subsidiaries, associates and other	-11,682,000	-8,595,000	14,023,932,000
Revenues per employee	552,144	488,134	465,289

Board of Directors

Charles Sawyers	Member of the administrative board
Nancy Andrews	Member of the administrative board
Simon Moroney	Member of the administrative board
Ana de Pro Gonzalo	Member of the administrative board
Bridgette Heller	Member of the administrative board
Daniel Hochstrasser	Member of the administrative board
Frans van Houten	Member of the administrative board
John Young	Member of the administrative board
Mary Doherty	Member of the administrative board
Patrice Bula	Member of the administrative board
Ton Büchner	Member of the administrative board
William Winters	Member of the administrative board
Hans Jörg Reinhardt	Chairman of the administrative board

Members of Management Board

Vasant (Vas) Narasimhan	Chairman of Managing Board
Klaus Moosmayer	Member of Executive Committee
Steffen Lang	Member of Executive Committee
Aharon Gal	Member of Executive Committee
Fiona H. Marshall	Member of Executive Committee
Harry Kirsch	Member of Executive Committee
Karen Hale	Member of Executive Committee
Kees Roks	Member of Executive Committee
Lutz Hegemann	Member of Executive Committee
Michelle Weese	Member of Executive Committee
Patrick Horber	Member of Executive Committee
Rob Kowalski	Member of Executive Committee
Shreeram Aradhye	Member of Executive Committee
Victor Bulto	Member of Executive Committee